Actavis UK Ltd and Others v Eli Lilly and Company: PatC 15 May 2014

The defendants owned a cancer treatment drugs patent which had been extended. The various claimants wished to introduce a generic version, and sought a declaration of invalidity of the patent.
Held: None of the Actavis products would directly or indirectly infringe the Patent in the UK or in France, Italy or Spain.
Arnold J
[2014] EWHC 1511 (Pat), [2014] 2 All ER (Comm) 669, [2014] 4 All ER 331, [2015] Bus LR 154, [2015] RPC 6
Bailii
England and Wales
Cited by:
At First InstanceEli Lilly v Actavis UK Ltd and Others SC 12-Jul-2017
The issue raised on this appeal and cross-appeal is whether three products manufactured by Actavis would infringe a patent whose proprietor is Lilly, namely European Patent (UK) No 1 313 508, and its corresponding designations in France, Italy and . .

These lists may be incomplete.
Updated: 13 February 2021; Ref: scu.525790